In recent trading session, Prime Medicine Inc (NASDAQ:PRME) saw 0.41 million shares changing hands at last check today with its beta currently measuring 2.04. Company’s recent per share price level of $1.78 trading at $0.06 or 3.78% at last check today assigns it a market valuation of $234.13M. That most recent trading price of PRME’s stock is at a discount of -364.61% from its 52-week high price of $8.27 and is indicating a premium of 3.93% from its 52-week low price of $1.71. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.53 million shares which gives us an average trading volume of 1.13 million if we extend that period to 3-months.

For Prime Medicine Inc (PRME), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.17. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.3 in the current quarter.

Prime Medicine Inc (NASDAQ:PRME) trade information

Upright in the green today for gaining 3.78%, in the last five days PRME remained trading in the red while hitting it’s week-highest on Monday, 03/10/25 when the stock touched $1.78 price level, adding 25.62% to its value on the day. Prime Medicine Inc’s shares saw a change of -38.87% in year-to-date performance and have moved -25.63% in past 5-day. Prime Medicine Inc (NASDAQ:PRME) showed a performance of -30.00% in past 30-days. Number of shares sold short was 18.04 million shares which calculate 17.29 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 17 to the stock, which implies a rise of 89.53% to its recent value today. Analysts have been projecting 12 as a low price target for the stock while placing it at a high target of 23. It follows that stock’s current price would drop -574.16% in reaching the projected high whereas dropping to the targeted low would mean a loss of -574.16% for stock’s current value.

Prime Medicine Inc (PRME) estimates and forecasts

This year revenue growth is estimated to rise 560.21% from the last financial year’s standing.

8 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 3.86M for the same. And 8 analysts are in estimates of company making revenue of 3.81M in the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -124.13% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 28.27% while estimates for its earnings growth in next 5 years are of 10.72%.

Prime Medicine Inc (NASDAQ:PRME)’s Major holders

Insiders are in possession of 23.91% of company’s total shares while institution are holding 59.05 percent of that, with stock having share float percentage of 77.60%. Investors also watch the number of corporate investors in a company very closely, which is 59.05% institutions for Prime Medicine Inc that are currently holding shares of the company. ALPHABET INC. is the top institutional holder at PRME for having 15.06 million shares of worth $77.42 million. And as of 2024-06-30, it was holding 12.6375 of the company’s outstanding shares.

The second largest institutional holder is ARK INVESTMENT MANAGEMENT LLC, which was holding about 6.13 million shares on 2024-06-30. The number of shares represents firm’s hold over 5.1404 of outstanding shares, having a total worth of $31.49 million.

On the other hand, ARK ETF Tr-ARK Genomic Revolution ETF and ARK ETF Tr-ARK Innovation ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024, the former fund manager was holding 2.41 shares of worth $4.32 million or 1.84% of the total outstanding shares. The later fund manager was in possession of 2.23 shares on Dec 31, 2024, making its stake of worth around $3.99 million in the company or a holder of 1.70% of company’s stock.